Abeona Therapeutics Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cleveland OH United States (2013)

Organization Overview

First Clinical Trial
2013
NCT01263379
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Abeona Therapeutics, Inc

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: Abeona Therapeutics (1) Acquired (2)

eb-101 (1 trial)

ofloxacin (floxin) (2 trials)

pexiganan acetate (2 trials)

Drugs in Phase 2 Trials (5)

Key: Abeona Therapeutics (3) Acquired (2)

amlexanox (aphthasol) (1 trial)

econazole (spectazole) (1 trial)

lzrse-col7a1 engineered autologous epidermal sheets (1 trial)

raav9.cmv.hnaglu (1 trial)

scaav9.u1a.hsgsh (2 trials)

Drugs in Phase 1 Trials (1)

Key: Abeona Therapeutics (0) Acquired (1)

Thiarabine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epidermolysis Bullosa (Phase 3)

Epidermolysis Bullosa Dystrophica (Phase 3)

Mucopolysaccharidoses (Phase 2)

Mucopolysaccharidosis III (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 9